Oxidative stress in hypertensive children before and after 1 year of antihypertensive therapy

Pediatric Nephrology

Volumn 27, Issue 10, 2012, Pages 1943-1951

  Śladowska Kozłowska, Joanna ^a   Litwin, Mieczysław ^a   Niemirska, Anna ^a   Płudowski, Paweł ^a   Wierzbicka, Aldona ^a   Skorupa, Ewa ^a   Wawer, Zbigniew T ^a   Janas, Roman ^a  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Antihypertensive therapy; Children; Insulin resistance; Metabolic syndrome; Oxidative stress; Primary hypertension; Target organ damage

Indexed keywords

ARGININE; C REACTIVE PROTEIN; DIMETHYLOARGININE; ENALAPRIL; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADOLESCENT; ANTIHYPERTENSIVE THERAPY; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CHILD; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OXIDATIVE STRESS; PRESCHOOL CHILD; PRIMARY HYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SCHOOL CHILD;

ADIPOSITY; ADOLESCENT; ALBUMINURIA; ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ARGININE; BIOLOGICAL MARKERS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CHOLESTEROL, LDL; FEMALE; GLUTATHIONE PEROXIDASE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INSULIN RESISTANCE; LIPOPROTEINS, LDL; MALE; METABOLIC SYNDROME X; OXIDATIVE STRESS; POLAND; SEVERITY OF ILLNESS INDEX; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866947753     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-012-2193-x     Document Type: Article

References (44)

1. Watanabe T, Yasunari K, Nakamura M, Maeda K (2006) Carotid artery intima-media thickness and reactive oxygen species formation by monocytes in hypertensive patients. J Human Hypertens 20:336-340
2. Turi S, Friedman A, Bereczki C, Papp F, Kovàcs J, Karg E, Németh I (2003) Oxidative stress in juvenile essential hypertension. J Hypertens 21:145-152
3. Jarvisalo MJ, Putto-Laurila A, Jartti L, Lehtimäki T, Solakivi T, Rönnemaa T, Raitakari OT (2005) Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes 51:493-498
4. Russo C, Olivieri O, Girelli D, Faccini G, Zenari ML, Lombardi S, Corrocher R (1998) Anti-oxidant status and lipid peroxidation in patients with essential hypertension. J Hypertens 16:1267-1271
5. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, Smieja M, Cambien F, Meyer J, Lackner KJ, Investigators AtheroGene (2003) Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Eng J Med 349:1605-1613
6. Pedro-Botet J, Covas MI, Martin S, Rubies-Prat J (2000) Decreased endogenous antioxidant enzymatic status in essential hypertension. J Hum Hypertens 14:343-345
7. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39:44-84
8. Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2003) Are oxidative stress activated signaling pathways mediations of insulin resistance and beta cell dysfunction? Diabetes 52:1-28
9. Sinaiko AR, Steinberger J, Moran A, Prineas RJ, Vessby B, Basu S, Tracy R, Jacobs DR (2005) Relation of body mass index and insulin resistance to cardiovascular risk factors, inflamatory factors, and oxidative stress during adolescence. Circulation 111:1985-1991
10. Kristal B, Shutz-Swirski R, Chezar J,Manaster J, Levy R, Shapiro G, Weissman I, Shasha SM, Sela S (1998) Participation of peripheral polymorphonuclear leukocytes in patients with essentials hypertension. Am J Hypertens 11:921-928
11. Perticone F, Sciacqua A, Maio R, Perticone M, Galiano Leone G, Bruni R, Di Cello S, Pascale A, Talarico G, Greco L, Andreozzi F, Sesti G (2010) Endothelial dysfunction, ADMA and insulin resistance in essentials hypertension. Int J Cardiol 142:236-241
12. Rudich A, Tirosh A, Potashnik R, Hemi R, Kanety H, Bashan N (1998) Prolonged oxidative stress impairs insulin-induced GLUT-4 translocation in 3 T3-L1 adipocytes. Diabetes 47:1562-1569
13. Park K, Gross M, Lee DH, Holvoet P, Himes JH, Shikany JM, Jacobs DR (2009) Oxidative stress and insulin resistance. The coronary artery risk development in young adults study. Diabetes 32:1302-1307
14. Melikoglu MA, Kaldirimci M, Katkat D, Sen I, Kaplan I, Senel K (2008) The effect of regular long term training on antioxidant enzymatic activities. J Sports Med Phys Fitness 48:388-390
15. Whyte JJ, Laughlin MH (2010) The effects of acute and chronic exercise on the vasculature. Acta Physiol 199:441-450
16. Yagi S, Morita T, Katayama S (2004) Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens Res 27:129-135
17. Ono H, Minatoguchi S, Watanabe K, Yamada Y, Mizukusa T, Kawasaki H, Takahashi H, Uno T, Tsukamoto T, Hiei K, Fujiwara H (2008) Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. Hypertens Res 31:271-279
18. Yasunari K, Maeda K, Watanabe T, Nakamura M, Yoshikawa J, Asada A (2004) Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. J Am Coll Cardiol 43:2116-2123
19. Baykal Y, Yilmaz MI, Celik T, Gok F, Rehber H, Akay C, Kocar IH (2003) Effects of antihypertensive agents, alpha receptor blockers, beta blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and calcium channel blockers, on oxidative stress. J Hypertens 21:1207-1211
20. Litwin M, Niemirska A, Śladowska-Kozłowska J, Wierzbicka A, Janas R, Wawer ZT, Wiśniewski A, Feber J (2010) Regression of target organ damage in children and adolescents with primary hypertension. Pediatr Nephrol 25:2489-2499
21. Śladowska-Kozłowska J, Litwin M, Niemirska A, Wierzbicka A, Wawer ZT, Janas R (2011) Change in left ventricular geometry during antihypertensive treatment in children with primary hypertension. Pediatr Nephrol 26:2201-2209
22. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) The Fourth Report on Diagnosis, Evaluation and Treatment of High Blood Pressure in Children and Adolescents Pediatrics 114:555-576
23. Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, Kuznetsova T, Laurent S, Mancia G, Morales-Olivas F, Rascher W, Redon J, Schaefer F, Seeman T, Stergiou G, Wühl E, Zanchetti A, European Society of Hypertension (2009) Management of high blood pressure in children and adolescents: recommendations of the European society of hypertension. J Hypertens 27:1719-1742
24. Wühl E, Witte K, Soergel M, Mehls O, Shaefer F, German Working Group on Pediatric Hypertension (2002) Distribution of 24-hambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens 20:1995-2007
25. Urbina E, Alpert B, Flynn J, Hayman L, Harshfield GA, Jacobson M, Mahoney L, McCrindle B, Mietus-Snyder M, Steinberger J, Daniels S, American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee (2008) Ambulatory blood pressure monitoring in children and adolescents recomendations for standard assessment. A scientific statement from the American heart association atherosclerosis, hypertension, and obesity in youth committee of the council on cardiovascular disease in the young and the council for high blood pressure research. Hypertension 52:433-451
26. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH (2000) Establishing a standard definition for child overweight and obesity worldwide: international study. BMJ 320:1240-1243
27. Litwin M, Śladowska J, Antoniewicz J, Niemirska A,Wierzbicka A, Daszkowska J, Wawer ZT, Janas R, Grenda R (2007) Metabolic abnormalities, insulin resistance and metabolic syndrome in children with primary hypertension. Am J Hypertens 20:875-882
28. Jourdan C, Wühl E, Litwin M, Fahr K, Trelewicz J, Jobs K, Schenk JP, Grenda R, Mehls O, Tröger J, Schaefer F (2005) Normative values of intima-media thickness and distensibility of large arteries in healthy adolescents. J Hypertens 23:1707-1715
29. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N (1986) Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57:450-458
30. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, AldermanMH(1992) Left ventricularmass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 20:1251-1260
31. Khoury PR, Mitsnefes M, Daniels SR, Kimball TR (2009) Agespecific reference intervals for indexed left ventricular mass in children. J Am Soc Echo 22:709-714
32. Daniels SR,Meyer RA, Liang Y, Bove KE (1998) Echocardiographically determined left ventricular mass index in normal children, adolescents and young adults. J Am Coll Cardiol 12:703-708
33. Redón J, Oliva MR, Tormos C, Giner V, Chaves J, Iraki A, Sáez GT (2003) Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 41:1096-1101
34. Kelly AS, Steinberger J, Kaiser DR, Olson TP, Bank AJ, Dengel DR (2006) Oxidative stress and adverse adipokine profile characterize the metabolic syndrome in children. J Cardiometab Syndr 1:248-252
35. Siemianowicz K, Gmiński J, Francuz T, Wójcik A, Posielezna B (2006) Activity of antioxidant enzymes in children from families at high risk of premature coronary heart disease. Scand J Clin Lab Invest 63:151-158
36. Sydov K, Mondon CE, Cooke JP (2005) Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc Med 10:35-43
37. Stühlinger M, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS (2002) Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. J Am Med Assoc 287:1420-1426
38. Goonasekera CD, Rees DD, Woolard P, Frend A, Shah V, Dillon MJ (1997) Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 15:901-909
39. Palm AJP, OnozatoML, Luo Z,Wilcox CS (2007) Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol 293:H3227-H3245
40. Kapur S, Bedard S, Marcotte B, Cote CH, Marette A (1997) Expression of nitric oxide synthase in skeletal muscle: a novel role for nitric oxide as a modulator of insulin action. Diabetes 46:1691-1700
41. Moreno MU, San José G, Fortuño A, Beloqui O, Díez J, Zalba G (2006) The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. J Hypertens 24:1299-306
42. Vaziri ND, Wang XQ, Oveisi F, Rad B (2000) Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 36:142-146
43. Touyz RM (2004) Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension 44:248-252
44. Brown LA, Kerr CJ, Whiting P, Finer R, McEneny J, Ashton T (2009) Oxidant stress in healthy normal-weight, overweight and obese individuals. Obesity 17:460-466